117 related articles for article (PubMed ID: 11752014)
1. Genetic analysis of the beta-tubulin gene, TUBB, in non-small-cell lung cancer.
Kelley MJ; Li S; Harpole DH
J Natl Cancer Inst; 2001 Dec; 93(24):1886-8. PubMed ID: 11752014
[No Abstract] [Full Text] [Related]
2. Beta-tubulin mutational analysis: tantalizing findings.
Rosell R; Tarón M; Sarries C; Queralt C; Roig B
Lung Cancer; 2002 Oct; 38(1):99-100. PubMed ID: 12367801
[No Abstract] [Full Text] [Related]
3. Conservation of the class I beta-tubulin gene in human populations and lack of mutations in lung cancers and paclitaxel-resistant ovarian cancers.
Sale S; Sung R; Shen P; Yu K; Wang Y; Duran GE; Kim JH; Fojo T; Oefner PJ; Sikic BI
Mol Cancer Ther; 2002 Jan; 1(3):215-25. PubMed ID: 12467216
[TBL] [Abstract][Full Text] [Related]
4. Re: Genetic analysis of the beta-tubulin gene, TUBB, in non-small-cell lung cancer.
Monzo M; Taron M; Rosell R
J Natl Cancer Inst; 2002 May; 94(10):774-6; author reply 777. PubMed ID: 12011232
[No Abstract] [Full Text] [Related]
5. Analysis of beta-tubulin gene alteration in human lung cancer cell lines.
Achiwa H; Sato S; Shimizu S; Maeda H; Niimi T; Takahashi T; Ueda R; Mitsudomi T
Cancer Lett; 2003 Nov; 201(2):211-6. PubMed ID: 14607336
[TBL] [Abstract][Full Text] [Related]
6. Mutational analysis of the beta-tubulin gene in lung cancer.
Tsurutani J; Komiya T; Uejima H; Tada H; Syunichi N; Oka M; Kohno S; Fukuoka M; Nakagawa K
Lung Cancer; 2002 Jan; 35(1):11-6. PubMed ID: 11750707
[TBL] [Abstract][Full Text] [Related]
7. Re: genetic analysis of the beta-tubulin gene, TUBB, in non-small-cell lung cancer.
Sale S; Oefner PJ; Sikic BI
J Natl Cancer Inst; 2002 May; 94(10):776-7; author reply 777. PubMed ID: 12011233
[No Abstract] [Full Text] [Related]
8. Absence of beta-tubulin gene mutation in gastric carcinoma.
Urano N; Fujiwara Y; Hasegawa S; Miyoshi Y; Noguchi S; Takiguchi S; Yasuda T; Yano M; Monden M
Gastric Cancer; 2003; 6(2):108-12. PubMed ID: 12861402
[TBL] [Abstract][Full Text] [Related]
9. Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations.
Monzó M; Rosell R; Sánchez JJ; Lee JS; O'Brate A; González-Larriba JL; Alberola V; Lorenzo JC; Núñez L; Ro JY; Martín C
J Clin Oncol; 1999 Jun; 17(6):1786-93. PubMed ID: 10561216
[TBL] [Abstract][Full Text] [Related]
10. Publishing negative data: beta-tubulin mutations in lung cancer.
Kaye FJ
J Natl Cancer Inst; 2001 Dec; 93(24):1832-3. PubMed ID: 11752001
[No Abstract] [Full Text] [Related]
11. Class III beta-tubulin mediates sensitivity to chemotherapeutic drugs in non small cell lung cancer.
Gan PP; Pasquier E; Kavallaris M
Cancer Res; 2007 Oct; 67(19):9356-63. PubMed ID: 17909044
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of an Australian testing programme for epidermal growth factor receptor mutations in non-small cell lung cancer.
Peters MJ; Bowden JJ; Carpenter P; Lewis J; Solomon B
Intern Med J; 2014 Jun; 44(6):575-80. PubMed ID: 24720523
[TBL] [Abstract][Full Text] [Related]
13. Tubulin-targeted drug action: functional significance of class ii and class IVb beta-tubulin in vinca alkaloid sensitivity.
Gan PP; Kavallaris M
Cancer Res; 2008 Dec; 68(23):9817-24. PubMed ID: 19047161
[TBL] [Abstract][Full Text] [Related]
14. [Analysis of EGFR mutations in 176 cases of non-small cell lung cancer].
Dong QG; Han BH; Huang JS; Yang LM; Huang J; Zhao CY; Lu LQ
Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):686-90. PubMed ID: 17274376
[TBL] [Abstract][Full Text] [Related]
15. Intron 1 CA dinucleotide repeat polymorphism and mutations of epidermal growth factor receptor and gefitinib responsiveness in non-small-cell lung cancer.
Han SW; Jeon YK; Lee KH; Keam B; Hwang PG; Oh DY; Lee SH; Kim DW; Im SA; Chung DH; Heo DS; Bang YJ; Kim TY
Pharmacogenet Genomics; 2007 May; 17(5):313-9. PubMed ID: 17429313
[TBL] [Abstract][Full Text] [Related]
16. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.
Azuma K; Sasada T; Kawahara A; Takamori S; Hattori S; Ikeda J; Itoh K; Yamada A; Kage M; Kuwano M; Aizawa H
Lung Cancer; 2009 Jun; 64(3):326-33. PubMed ID: 18977553
[TBL] [Abstract][Full Text] [Related]
17. Analysis of tubulin isotypes and mutations from taxol-resistant cells by combined isoelectrofocusing and mass spectrometry.
Verdier-Pinard P; Wang F; Martello L; Burd B; Orr GA; Horwitz SB
Biochemistry; 2003 May; 42(18):5349-57. PubMed ID: 12731876
[TBL] [Abstract][Full Text] [Related]
18. Are exon 19 deletions and L858R EGFR mutations in non-small-cell lung cancer clinically different?
Costa DB; Kobayashi S
Br J Cancer; 2007 Jan; 96(2):399; author reply 400. PubMed ID: 17224926
[No Abstract] [Full Text] [Related]
19. Expression of ERCC1 and class IIIbeta tubulin for predicting effect of carboplatin/paclitaxel in patients with advanced inoperable non-small cell lung cancer.
Ikeda S; Takabe K; Suzuki K
Pathol Int; 2009 Dec; 59(12):863-7. PubMed ID: 20021611
[TBL] [Abstract][Full Text] [Related]
20. Frequency of EGFR T790M mutation and multimutational profiles of rebiopsy samples from non-small cell lung cancer developing acquired resistance to EGFR tyrosine kinase inhibitors in Japanese patients.
Ko R; Kenmotsu H; Serizawa M; Koh Y; Wakuda K; Ono A; Taira T; Naito T; Murakami H; Isaka M; Endo M; Nakajima T; Ohde Y; Yamamoto N; Takahashi K; Takahashi T
BMC Cancer; 2016 Nov; 16(1):864. PubMed ID: 27821131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
